OGN 📈 Organon - Overview

Organon & Co, a global healthcare company, develops and delivers a wide range of health solutions through its diverse portfolio of prescription therapies and medical devices, with a strong focus on women's health. The company's women's health portfolio includes a variety of contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive, and NuvaRing, a monthly vaginal contraceptive ring. Additionally, it offers Cerazette, a daily pill used to prevent pregnancy, as well as Marvelon, which combines progestin and estrogen as daily pills to prevent pregnancy. The company also provides Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures, and Elonva, an ovarian follicle stimulant. Furthermore, its portfolio includes Ganirelix Acetate Injection, an injectable antagonist, and Jada, used to treat abnormal postpartum uterine bleeding or hemorrhage.

Organon & Co's biosimilars portfolio is comprised of immunology products, including Brenzys, Renflexis, and Hadlima, as well as two oncology products, Ontruzant and Aybintio. The company also offers a range of cholesterol-modifying medicines under various brand names, such as Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor. Its cardiovascular portfolio includes Cozaar and Hyzaar, used to treat hypertension. The company's respiratory products, including Singulair, Dulera, Zenhale, and Asmanex, are used to control and prevent symptoms caused by asthma. It also offers Singulair, Nasonex, Clarinex, and Aerius for the treatment of seasonal allergic rhinitis. Moreover, the company provides dermatology products under the Diprosone and Elocon brand names, as well as a bone health portfolio, including the Fosamax brand name.

Organon & Co's product portfolio extends to non-opioid pain management, with products such as Arcoxia, Diprospan, and Celestone. The company also offers Proscar for the treatment of symptomatic benign prostatic hyperplasia and Propecia for the treatment of male pattern hair loss. Its products are sold to a wide range of customers, including drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. With its incorporation in 2020 and headquarters in Jersey City, New Jersey, Organon & Co operates as a global healthcare company, providing a diverse range of health solutions to its customers. The company's website can be found at https://www.organon.com, and its common stock is listed under the ISIN US68622V1061, classified under the GICS Sub Industry: Pharmaceuticals.